Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease

Medicinal Research Reviews

Volumn 23, Issue 1, 2003, Pages 15-31

  Kurogi, Yasuhisa ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Glomerular disease; Mesangial cell; Proliferation inhibitors

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIMITOTIC AGENT; CANDESARTAN; CAPTOPRIL; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENALAPRIL; GA 0113; HALOFUGINONE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LISINOPRIL; MATRIX METALLOPROTEINASE INHIBITOR; MEVINOLIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N1 [2,2 DIMETHYL 1 [(METHYLAMINO)CARBONYL]PROPYL] N4 HYDROXY 2 (2 METHYLPROPYL)BUTANEDIAMIDE; PLATELET DERIVED GROWTH FACTOR; PRAVASTATIN; RAMIPRIL; RAPAMYCIN; ROSCOVITINE; SIMVASTATIN; TACROLIMUS; TRAPIDIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; DIABETIC NEPHROPATHY; DRUG MECHANISM; EXTRACELLULAR MATRIX; GLOMERULOPATHY; GLOMERULOSCLEROSIS; GLOMERULUS CAPILLARY; HEMODYNAMICS; HUMAN; HUMAN CELL; IMMUNOGLOBULIN A NEPHROPATHY; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROMOLECULE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MESANGIUM CELL; NONHUMAN; PHAGOCYTOSIS; PROTEIN RESTRICTION; RAT; STRUCTURE ACTIVITY RELATION;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CELL DIVISION; ENZYME INHIBITORS; GLOMERULAR MESANGIUM; GLOMERULONEPHRITIS, IGA; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOTRIENE D4; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, ANGIOTENSIN; RECEPTORS, ESTROGEN;

EID: 0037217177     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10028     Document Type: Article

References (58)

1. MEDLINEplus Health Information, http://medlineplus.gov/
2. Couser WG. Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant 1998;13(Suppl 1):10-15.
3. Salvetti A, Mattei P, Sudano I. Renal protection and antihypertensive drugs: Current status. Drugs 1999;57:665-693.
4. Woo KT, Lau YK. Proteinuria: Clinical signficance and basis for therapy. Singapore Med J 2001;42:385-389.
5. Nakamura T, Obata J, Kimura H, Ohno S, Yoshida Y, Kawaihi H, Shimizu F. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 1999;55:877-889.
6. Ruiz-Gines JA, Perez-Caballero C, O'Valle F, Rodriguez-Puyol M, Rodriguez-Puyol D. Captopril inhibits pp60(c-src) tyrosine phosphorylation in cultured human mesangial cells. Eur J Pharmacol 1997;336:251-256.
7. Kuriyama S, Shimada T, Hashimoto T, Sakai O. Captopril ameliorates the posturally induced fall in creatinine clearance in patients with chronic glomerulonephritis. Pharmacotherapy 1992;12:158-160.
8. Grandaliano G, Ranieri E, Monno R, Gesualdo L, Schena F. Ramipril inhibits in vitro human mesangial cell proliferation and platelet-derived growth factor expression. Exp Nephrol 1999;7:229-235.
9. Nishikawa K. Angiotensin ATI receptor antagonism and protection against cardiovascular end-organ damage. J Hum Hypertens 1998;12:301-309.
10. Mise N, Kimura K, Kurabayashi M, Nagai R, Okuda T, Ohba S, Suzuki N, Miyashita K, Kamijo A, Tojo A, Goto A, Omata M. Angiotensin II enhances glomerular expression of a nonmuscle myosin heavy chain, SMemb, with extracellular matrix accumulation. Nephron 2002;90:477-483.
11. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol 2000;20:373-379.
12. Ebisu H, Nishikawa M, Tanaka M, Okazoe T. Morizawa Y, Shinyama H, Nakamura N. Pharmacologic profiles of GA0113, a novel quinoline derivative angiotensin II ATI-receptor antagonist. J Cardiovasc Pharmacol 1999;34:526-532.
13. Shultz P, Raij L. Effect of amlodipine on mesangial cell proliferation and protein synthesis. Am J Hypertens 1992;5:912-914.
14. Nayler WG. Amlodipine. Berlin-Heidelberg-New York: Springer; 1993; Latta G, Schrör K, Kalziumantagonisten und Thrombozytenfunktion. Haemostaseologie 1988;8:1-9.
15. Nayler WG. Amlodipine. Berlin-Heidelberg-New York: Springer; 1993; Latta G, Schrör K, Kalziumantagonisten und thrombozytenfunktion. Haemostaseologie 1988;8:1-9.
16. Steffen HM. Amlodipine - A third generation dihydropyridine calcium antagonist. J Clin Basic Cardiol 1999;2:45-52.
17. Toogood PL. Cyclin-dependent kinase inhibitors for treating cancer. Med Res Rev 2001;21:487-498.
18. Knockaert M, Gray N, Damiens E, Chang Y-T, Grellier P, Grant K, Fergusson D, Mottram J, Soete M, Dubremetz J-F, Roch KL, Doerig C, PG Schultz PG, Meijer L. Intracellular targets of cyclin-dependent kinase inhibitors: Identification by affinity chromatography using immobilised inhibitors. Chem Biol 2000;7:411-422.
19. Pippin JW, Qu Q, Meijer L, Shankland SJ. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel cyclin-dependent kinase antagonist. J Clin Invest 1997;100:2512-2520.
20. Marti HP. New strategy to treat glomerular inflammation by inhibition of mesangial cell matrix metalloproteinases. Schweiz Med Wochenschr 2000;130:784-788.
21. Marti HP, McNeil L, Thomas G, Davies M, Lovett DH. Molecular characterization of a low molecular weight matrix metalloproteinase secreted by glomerular mesangial cells as Pump-1. Biochem J 1992;285:899-905.
22. Koide H, Nakamura T, Ebihara I, Tomino Y. Increased mRNA expression of metalloproteinase-9 in peripheral blood monocytes from patients with immunoglobulin A nephropathy. Am J Kidney Dis 1996;28:32-39.
23. Ebihara I, Nakamura T, Noriaki S, Koide H. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin dependent diabetes mellitus. Am J Kidney Dis 1998;32:544-550.
24. Steinmann-Niggli K, Lukes M, Marti HP. Rat mesangial cells and matrix metalloproteinase inhibitor: Inhibition of 72-kD type IV collagenase (MMP-2) and of cell proliferation. J Am Soc Nephrol 1997;8:395-405.
25. Daniel C, Duffield J, Brunner T, Steinmann-Niggli K, Lods N, Marti HP. Matrix metalloproteinase inhibitors cause cell cycle arrest and apoptosis in glomerular mesangial cells. J Pharmacol Exp Ther 2001;297:57-68.
26. Nagler A, Katz A, Aingorn H, Miao HQ, Condiotti R, Genina O 0, Pines M, Vlodavsky I. Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone. Kidney Int 1997;52:1561-1569.
27. Elkin M, Reich R, Nagler A, Aingorn E, Pines M, de-Groot N, Hochberg A, Vlodavsky I. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin Cancer Res 1999;5:1982-1988.
28. Haas CS, Schocklmann HO, Lang S, Kralewski M, Sterzel RB. J Nephrol 1999;12:405-415.
29. Radeke HH, Kuster S, Kaever V, Resch K. Effects of cyclosporin and FK-506 on glomerular mesangial cells. Evidence for direct inhibition of thromboxane synthase by low cyclosporin concentrations. Eur J Clin Pharmacol 1993;44(Suppl 1):S11-S16.
30. Wang W, Chan YH, Lee W, Chan L. Effect of rapamycin and FK506 on mesangial cell proliferation. Transplant Proc 2001;33:1036-1037.
31. Ziswiler R, Steinmann-Niggli K, Kappeler A, Daniel C, Marti HP. Mycophenolic acid: A new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 1998;9:2055-2066.
32. Hauser IA, Renders L, Radeke HH, Sterzel RB, Goppelt-Struebe M. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999;14:58-63.
33. Nishimura M, Tanaka T, Yasuda T, Kurakata S, Kitagawa M, Yamada K, Saito Y, Hirai A. Effect of pravastatin on type IV collagen secretion and mesangial cell proliferation. Kidney Int Suppl 1999;71:S97-S100.
34. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993;91:83-87.
35. Terada Y, Inoshita S, Nakashima O, Yamada T, Kuwahara M, Sasaki S, Marumo F. Lovastatin inhibits mesangial cell proliferation via p27Kip1. J Am Soc Nephrol 1998;9:2235-2243.
36. Yoshimura A, Nemoto T, Sugenoya Y, Inui K, Watanabe S, Inoue Y, Sharif S, Yokota N, Uda S, Morita H, Ideura T. Effect of simvastatin on proliferative nephritis and cell-cycle protein expression. Kidney Int Suppl 1999;71:S84-S87.
37. Grandaliano G, Biswas P, Choudhury GG, Abboud HE, Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 1993;44:503-508.
38. Iida H, Seifert R, Alpers CE, Gronward RG, Phillips PE, Pritzl P, Gordon K, Gown A, Ross R, Bown-Pope D, Johnson R. Platelet-derived growth factor and PDGF receptor expression in mesangial proliferative nephritis. Proc Natl Acad Sci USA 1991;88:6560-6564.
39. Futamura A, Izumino K, Nakagawa Y, Takata M, Inoue H, Iida H. Effect of the platelet-derived growth factor antagonist trapidil on mesangial cell proliferation in rats. Nephron 1999;81:428-433.
40. Gesualdo L, Di Paolo S, Ranieri E, Schena FP. Trapidil inhibits human mesangial cell proliferation: Effect on PDGF beta-receptor binding and expression. Kidney Int 1994;46:1002-1009.
41. Hillis GS, Duthie LA, MacLeod AM. Dipyridamole inhibits human mesangial cell proliferation. Nephron 1998;78:172-178.
42. Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 2001;59:1324-1332.
43. Haraguchi M, Okamura M, Konishi M, Konishi Y, Negoro N, Inoue T, Kanayama Y, Yoshikawa J. Anti-angiogenic compound (TNP-470) inhibits mesangial cell proliferation in vitro and in vivo. Kidney Int 1997;51:1838-1846.
44. Kato S, Fujisawa A, Nanayama T. Japanese Patent: JP2001089471.
45. Badr KF, De Boer DK, Schwartzberg M, Serhan CN. Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: Evidence for competition at a common receptor. Proc Natl Acad Sci USA 1989;86:3438-3442.
46. Papayianni A, Serhan CN, Brady HR. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J Immunol 1996;156:2264-2272.
47. McMahon B, Stenson C, McPhillips F, Fanning A, Brady HR, Godson C. Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors. J Biol Chem 2000;275:27566-27575.
48. Abboud HE, Bhandari B, Ghosh Choudhury G. Cell biology of platelet-derived growth factor. In: Bonventre J, Schlondorf D, editors. Molecular Nephrology. Kidney Function in Health and Disease. New York: Dekker; 1995. p 573-590.
49. Ghosh PM, Mikhailova M, Bedolla R, Kreisberg JI. Arginine vasopressin stimulates mesangial cell proliferation by activating the epidermal growth factor receptor. Am J Physiol Renal Physiol 2001;280:F972-F979.
50. Parameswaran N, Spielman WS, Brooks DP, Nambi P. SB203580 reverses adrenomedullin's effect on proliferation and apoptosis in cultured mesangial cells. Eur J Pharmacol 1999;371:75-82.
51. Xiao S, Gillespie DG, Baylis C, Jackson EK, Dubey RK. Effects of estradiol and its metabolites on glomerular endothelial nitric oxide synthesis and mesangial cell growth. Hypertension 2001;37:645-650.
52. Haneda M, Araki S, Sugimoto T, Togawa M, Koya D, Kikkawa R. Differential inhibition of mesangial MAP kinase cascade by cyclic nucleotide. Kidney Int 1996;50:384-391.
53. Mené P, Dunn MJ. Prostaglandins and rat glomerular mesangial cell proliferation. Kidney Int 1990;37:1256-1262.
54. Togawa M, Haneda M, Araki S, Sugimoto T, Isono M, Hidaka H, Yasuda H, Kashiwagi A, Kikkawa R. Beraprost sodium, an analogue of prostacyclin, induces the expression of mitogen-activated protein kinase phosphatase and inhibits the proliferation of cultured mesangial cells. Eur J Pharmacol 1997;336:291-294.
55. Segawa K, Minami K, Shiga Y, Shiraishi M, Sata T, Nakashima Y, Shigematsu A. Inhibitory effects of nicorandil on rat mesangial cell proliferation via the protein kinase G pathway. Nephron 2001;87:263-268.
56. Jimi N, Segawa K, Minami K, Sata T, Shigematsu A. Inhibitory effect of the intravenous anesthetic, ketamine, on rat mesangial cell proliferation. Anesth Analg 1997;84:190-195.
57. Kurogi Y, Güner O. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr Med Chem 2001;8:1035-1055.
58. Kurogi Y, Miyata K, Okamura T, Hashimoto K, Tsutsumi K, Nasu M, Moriyasu M. Discovery of novel mesangial cell proliferation inhibitors using three-dimensional database searching method. J Med Chem 2001;44:2304-2307.